CD73 Inhibitor

AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a K_i of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.

PSB-12379, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with K_is of 9.03 nM (rat) and 2.21 nM (human).

MethADP (Adenosine 5'-(α,β-methylene)diphosphate) triammonium is a CD73 inhibitor. MethADP can be used for the research of ATP-adenosine pathway.

Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity.

Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73^POS B cells.

PM-1015 is a specific antibody targeting CD73. PM-1015 can be used for the research of advanced solid tumor.

PF-1010 is a CD73 inhibitor with an IC₅₀ ranging from 101 to 1000 nM. PF-1010 blocks the interaction between CD73 protein and its substrate, and inhibits the enzymatic activity of CD73. PF-1010 is applicable to the research of cancer, infectious diseases, autoimmune diseases and neurodegenerative diseases.

PSB-24379 is a CD39 inhibitor that potently inhibits human membrane-bound CD39 (K_i = 77.4 nM) and truncated soluble human CD39 (K_i = 23.1 nM). PSB-24379 reduces the level of ATP hydrolysis in melanoma and breast cancer cell membranes. PSB-24379 partially reverses ATP-mediated suppression of T cell activation and proliferation in a high-ATP environment. PSB-24379 can be used in research related to melanoma and breast cancer.

Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer.

MethADP is a specific CD73 inhibitor.

Anti-Mouse CD73 Antibody (TY/23) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD73. Anti-Mouse CD73 Antibody (TY/23) can neutralize CD73. Anti-Mouse CD73 Antibody (TY/23) can be used for the researches of cancer, infection and immunology, such as B16F10 tumor and murine cytomegalovirus infection.

CD73-IN-5 is a potent and selective non-nucleotide small molecule inhibitor of CD73 (IC₅₀ = 19 nM).

CD73-IN-1 is an inhibitor of CD73 which can be used in the treatment of cancer extracted from patent WO 2017153952 A1, example 80.

CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor, with an IC₅₀ of 2.6 nM for human CD73. CD73-IN-4 is potential for the research of cancer immunology.

CD73-IN-3 is a potent CD73 inhibitor (IC₅₀=7.3 nM in Calu6 human cell assay). CD73-IN-3, example 2 extracted from patent WO2019168744 A1, has the potential for cancer research.

OP-5244 is a potent and orally active inhibitor of CD73, with an IC₅₀ of 0.25 nM. OP-5244 reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research.

OP-5244 sodium is a potent and orally active inhibitor of CD73, with an IC₅₀ of 0.25 nM. OP-5244 sodium reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research.

Dalutrafusp alfa (AGEN-1423; GS-1423) is a specific bifunctional antibody against CD73 and TGF-β, which is involved in the immunosuppressive pathway.

8-BuS-AMP is a NTPDase1 inhibitor and a CD73/CD39 inhibitor, with an IC₅₀ of 35 μM and a K_i value of 0.292 μM against human NTPDase1; its K_i values against human CD73 and CD39 are 1.19 μM and 0.847 μM, respectively. 8-BuS-AMP binds to the substrate-binding pockets of NTPDase1 and CD73 to effectively block the conversion of ATP and AMP to adenosine, thereby enhancing the activation and proliferation of human peripheral T lymphocytes. 8-BuS-AMP possesses excellent enzymatic hydrolysis resistance and metabolic stability, resists hydrolysis by multiple NTPDase subtypes, and shows no activity against P2Y1 and P2Y12 receptors. 8-BuS-AMP can be used in purinergic signaling pathway and cancer-related studies.

AB-680 ammonium is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a K_i of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.